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Abstract
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are associated with loss 
of nuclear TDP-43. Here we identify that TDP-43 regulates expression of the neuronal growth-
associated factor stathmin-2. Lowered TDP-43 levels, which reduce its binding to sites within the 
first intron of stathmin-2 pre-mRNA, uncover a cryptic polyadenylation site whose utilization 
produces a truncated, non-functional mRNA. Reduced stathmin-2 expression is found in neurons 
trans-differentiated from patient fibroblasts expressing an ALS-causing TDP-43 mutation, in 
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motor cortex and spinal motor neurons from sporadic ALS patients and familial ALS patients with 
expansion in C9orf72, and in induced pluripotent stem cell (iPSC)-derived motor neurons depleted 
of TDP-43. Remarkably, while reduction in TDP-43 is shown to inhibit axonal regeneration of 
iPSC-derived motor neurons, rescue of stathmin-2 expression restores axonal regenerative 
capacity. Thus, premature polyadenylation-mediated reduction in stathmin-2 is a hallmark of 
ALS/FTD that functionally links reduced nuclear TDP-43 function to enhanced neuronal 
vulnerability.
Introduction
Amyotrophic lateral sclerosis (ALS) is a late-onset neurodegenerative disease of the motor 
system, characterized by selective and progressive loss of motor neurons, eventually leading 
to paralysis and death within 2–5 years 1. Ninety percent of ALS cases are not associated 
with a family history and referred to as sporadic ALS. The remaining ten percent are caused 
by inherited mutations in a variety of genes, including the most frequent genetic cause of 
ALS represented by GGGGCC repeat expansions in the C9orf72 gene 2,3. Notably, many of 
the genes whose mutation is linked to ALS also cause or contribute to another age-
dependent neurodegenerative disorder frontotemporal dementia (FTD). A landmark 
contribution to understanding cellular mechanisms of ALS and FTD came from the 
discovery of cytoplasmic accumulation and nuclear loss of the RNA binding protein TDP-43 
from affected neurons in most instances of ALS, as well as in approximately 45% of patients 
with FTD 4,5. Over 40 dominantly inherited mutations in the gene encoding TDP-43 have 
subsequently been identified in familial ALS patients 6, implicating TDP-43 dysfunction in 
the vast majority of ALS cases.
TDP-43 is involved in fundamental RNA processing activities including RNA transcription, 
splicing, and transport 7–10. TDP-43 binds to thousands of pre-mRNA/mRNA targets, with 
high affinity for GU-rich sequences, including autoregulation of its own mRNA via binding 
to the 3’ untranslated region (3’ UTR) 8,9,11. Reduction in TDP-43 from an otherwise 
normal adult nervous system alters the splicing or expression levels of more than 1500 
RNAs, including long intron-containing transcripts 8,12. Considering the central role of 
TDP-43 in RNA metabolism, it is anticipated that loss of nuclear TDP-43 in affected 
neurons of ALS and FTD patients drives processing alterations of multiple RNAs 8,12. 
However, a direct link to neuronal degeneration from reduction or mutation in TDP-43 
remains elusive.
Microtubules are key components of the neuronal cytoskeleton, essential for maintaining the 
stability, shape and proper function of the neuron 13. An intrinsic property of microtubules is 
their “dynamic instability” 14, i.e., the ability to switch between rapid polymerization and 
rapid shrinkage (known as catastrophe) in a process that is largely dampened by 
microtubule-associated proteins 15. One of these (encoded by the STMN2 gene) is the 
neuronal stathmin-2 (also known as SCG10), which is thought to play an important role in 
neurite outgrowth 16, most likely by promoting microtubule dynamics in axonal growth 
cones 17,18. The four proteins of the stathmin family, each encoded by a different gene, 
affect microtubule dynamics by either directly promoting catastrophe 19 or sequestering 
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tubulin to prevent assembly 20. Stathmin-2, the only essential mammalian stathmin 20, 
contains two tubulin-binding domains and a conserved N-terminal membrane-anchoring 
domain containing two palmitoylation sites 16,20.
Stathmin-2 is anterogradely transported along axons 21 and has been implicated as an 
essential component for axonal regeneration 20. Upon axonal injury, stathmin-2 is 
upregulated and recruited to growth cones of regenerating axons 22. Moreover, stathmin-2 
has been proposed as an axonal-maintenance factor whose loss accelerates a neuronal 
degeneration program 21. In Drosophila, expression of a mutant stathmin causes retraction of 
motor neurons from innervated neuromuscular junctions 23.
We now identify that the mRNA encoding stathmin-2 is significantly lost after TDP-43 
depletion and in neurons trans-differentiated from multiple patient fibroblasts, each carrying 
an ALS-causing mutation in TDP-43. Mechanistically, TDP-43 disruption is shown to drive 
premature polyadenylation and aberrant splicing in intron one of stathmin-2 pre-mRNA, 
producing a non-functional mRNA. Aberrant polyadenylation/splicing of stathmin-2 pre-
mRNA is also consistently found in spinal motor neurons and motor cortex of sporadic ALS 
and C9orf72 ALS patients, supporting stathmin-2 loss of function as a key driver of motor 
neuron degeneration. Indeed, suppression of TDP-43 or stathmin-2 in iPSC-derived motor 
neurons leads to inhibition of axonal regeneration after induced damage. Importantly, 
restoration of stathmin-2 levels rescues axonal regeneration ability in the absence of 
TDP-43, evidence supporting rescue of stathmin-2 levels as a potential therapeutic approach 
in neurodegenerative diseases – especially ALS and FTD – affected by TDP-43 
proteinopathy.
Results
TDP-43 depletion or disease-causing mutation suppresses stathmin-2
Two independent strategies were undertaken to manipulate TDP-43 function in a human 
neuronal cell line: 1) depletion of TDP-43 by siRNA and 2) genome editing with CRISPR-
Cas9 to introduce an ALS-causing mutation into both endogenous TDP-43 gene loci. The 
human neuronal cell line SH-SY5Y was chosen as a model as it has been shown to maintain 
a diploid karyotype and acquire substantial neuronal character when differentiated 24. siRNA 
treatment reduced TDP-43 mRNA levels by >80% when compared to cells treated with a 
control siRNA (Fig. 1a). The consequences of lowering TDP-43 were then examined on a 
genome-wide basis. Libraries of RNAs were prepared, sequenced, and mapped to the human 
genome. This approach confirmed reduction of TDP-43 to 1/4th of its initial level (Fig. 1b). 
Amid 299 and 219 mRNAs that were down or up regulated, respectively (with fold changes 
>1.5, false discovery rate [FDR] <0.05) (Supplementary Table 1), the most affected mRNA 
(with >85% reduction - Fig. 1b and Supplementary Fig. 1a) was the one encoding the 
neuronal growth-associated protein stathmin-2 16,18. Reduction in stathmin-2 mRNA upon 
TDP-43 depletion was confirmed by quantitative PCR (qPCR) (Fig. 1c) and an 8-fold 
reduction of the 22 kD stathmin-2 protein was identified by immunoblotting (Fig. 1d and 
Supplementary Fig. 1b).
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Using a CRISPR-Cas9 site-selective nuclease, we next genetically engineered SH-SY5Y 
cells to express a familial ALS-causing mutation (asparagine substituted to serine at amino 
acid 352 – TDP-43N352S) from both endogenous TDP-43 alleles (Supplementary Fig. 2a). 
Immunofluorescence imaging confirmed that mutant TDP-43 protein remained mostly 
nuclear, similar to wild type TDP-43 expressed in the original SH-SY5Y line (Fig. 1e and 
Supplementary Fig. 2b). Transcriptional profiling (i.e., RNA-seq) of the wild type and 
mutant lines revealed that introduction of the disease-causing TDP-43 mutation led to 
altered expression of 950 mRNAs (451 downregulated and 499 upregulated; fold change 
>1.5, FDR <0.05) (Supplementary Table 2), including moderate reduction in TDP-43 (Fig. 
1f). In addition, previously described alternative splicing changes linked to TDP-43 loss of 
function were observed in TDP-43 mutant-expressing cells (Supplementary Fig. 2c), 
consistent with both loss of normal TDP-43 function and a gain of aberrant function, as seen 
previously in mice 25–27.
Analysis of RNAs from isogenic wild type and mutant lines (using qPCR) confirmed a 1.7 
fold reduction of stathmin-2 mRNA (Fig. 1g), while immunoblotting revealed more than two 
fold reduction of stathmin-2 protein in TDP-43N352S mutant cells (Supplementary Fig. 2d). 
A search for gene expression changes that overlapped between cells with TDP-43 loss of 
function (Fig. 1b) and TDP-43N352S mutant cells (Fig. 1f) identified stathmin-2 mRNA (and 
18 additional RNAs) to be downregulated, together with another 23 that were upregulated 
(Fig. 1h).
Reduced stathmin-2 in TDP-43 mutant human neurons
We then tested whether stathmin-2 expression was reduced in human neurons directly 
converted from ALS patients’ fibroblasts. To this end, we used eight fibroblast lines obtained 
from an extended family that included four carriers heterozygous for the ALS-linked mutant 
TDP-43N352S and four individuals without the mutation (Supplementary Fig. 3a and 
Supplementary Table 3). Overall stathmin-2 mRNA levels were already reduced (by 50%) 
(Supplementary Fig. 3b) in the mutant fibroblast lines relative to controls despite primarily 
nuclear localization of TDP-43 protein both in control and ALS patient fibroblasts 
(Supplementary Fig. 3c-d). Fibroblasts from all eight lines were directly induced into 
neurons (herein referred to as iNeurons) 28 by expression of the neuronal-specific 
transcription activator Brn2 and reduction of the RNA-binding protein PTB (Fig. 2a).
TDP-43 was almost exclusively nuclear in wild type and mutant fibroblasts (Supplementary 
Fig. 3c-d). When converted into iNeurons, a higher proportion of wild type TDP-43 
accumulated in the cytoplasm and this relocalization was enhanced in iNeurons expressing 
the N352S mutation (Fig. 2b and Supplementary Fig. 3e). Importantly, stathmin-2 mRNA 
was significantly downregulated (more than 3 fold) in all four sets of TDP-43N352S iNeurons 
relative to the four iNeuron lines derived from fibroblasts of healthy family members 
(p<0.01, n=4) (Fig. 2c).
We next tested iNeurons generated from familial ALS patient fibroblasts carrying three other 
mutations: glycine to serine at position 298 (TDP-43G298S), alanine to threonine at position 
382 (TDP-43A382T), and asparagine to serine at position 390 (TDP-43N390S). Stathmin-2 
mRNA was reduced (relative to iNeurons from non-ALS individuals) in all of these familial 
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ALS iNeurons (Fig. 2c-d). These data demonstrate that, similar to reduction of TDP-43, 
ALS-linked mutations in TDP-43 suppress stathmin-2 expression level in human iNeurons.
TDP-43 represses premature polyadenylation in stathmin-2 pre-mRNA
The stathmin-2 gene is annotated to contain 5 constitutive exons (Refseq ID: 
NM_001199214.1) plus a proposed alternative exon between exons 4 and 5 whose use was 
undetectable (using RNA-seq) under any condition in our SH-SY5Y cells (Fig. 3a). 
Reduction or mutation in TDP-43, however, induced a new spliced exon, with RNA-seq 
reads mapping within intron one (Fig. 3a, red arrow). This new exon, herein called “exon 
2a”, was absent in wild type cells, but appeared either when TDP-43 was depleted or when 
endogenous TDP-43 was edited to carry the N352S mutation. Prominent utilization of this 
new exon was observed when TDP-43 was reduced, in line with >6 fold suppression of 
RNAs containing exons 2 through 5 (Fig. 3a, upper panel). This was accompanied by the 
corresponding loss of stathmin-2 protein (Fig. 1d and Supplementary Fig. 1b).
Altered splicing and ligation of exon 1 to exon 2a in SH-SY5Y cells after TDP-43 depletion 
or in the presence of a TDP-43 mutation was then confirmed by RT-PCR and qPCR (Fig. 
3b). However, while fusion between exon 1 and exon 2a was consistently observed (Fig. 3b), 
no RNAs containing exon 2a ligated to the downstream exon 2 were identified using primers 
targeting the flanking exons 1 and 2 (Supplementary Fig. 4a-c). To test the possibility that 
incorporation of exon 2a drives alternative polyadenylation within what is normally intron 
one (Fig. 3c), we used anchored oligo(dT) primers for reverse transcription followed by PCR 
and sequencing. This analysis confirmed polyadenylation of the stathmin-2 RNA containing 
exon 2a as the terminal exon (Fig. 3d-e).
A polyadenylation signal “AUUAAA” 29 was identified 24 nucleotides upstream to the 
polyadenylation site (Fig. 3d). This cryptic polyadenylation sequence in the human 
stathmin-2 gene is conserved among most primates, but is notably absent in mouse or rat 
(Supplementary Fig. 4d). qPCR analysis on nascent stathmin-2 pre-mRNAs identified 
reduction in full-length stathmin-2 transcripts in SH-SY5Y cells expressing mutant TDP-43 
(Supplementary Fig. 4e), consistent with increased levels of truncated exon 2a-containing 
RNAs (Fig. 3b).
The prematurely polyadenylated RNA includes 227 nucleotides originating from exon 2a 
(hg38; chr8:79,616,822–79,617,048) with its predicted 16 amino acid translation product 
initiating at the normal AUG codon in exon 1 and ending at 11 codons into exon 2a (Fig. 3c-
d). Three “GUGUGU” hexamers marking potential binding sites of TDP-43 (as we and 
others have previously described 8,9) were identified in a region spanning 30 nucleotides 
downstream of the 3’ splice site that produces exon 2a (Fig. 3d). Indeed, analysis of 
ultraviolet cross-linking and immuno-precipitation (iCLIP) data for TDP-43 in human SH-
SY5Y cells 9, confirmed TDP-43 binding (shown by mapped reads) to the stathmin-2 pre-
mRNA at a single region containing the three GUGUGU sequences (Fig. 3f), thus 
confirming physical interaction with TDP-43 protein. Altogether, we conclude that reduction 
in TDP-43 causes de-repression and efficient use of a cryptic polyadenylation site in what 
normally is intron 1, which results in truncation of the stathmin-2 pre-mRNA and 
suppression of functional stathmin-2 expression.
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Stathmin-2 mRNA is prominently expressed in motor neurons
Comparison of published evidence of the abundance of stathmin-2 mRNA in ribosome-
bound RNAs across specific cell types of the murine central nervous system 30 revealed 25 
and 15 fold enrichment of translated stathmin-2 mRNAs in motor neurons relative to 
astrocytes and oligodendrocytes, respectively (Supplementary Fig. 5a). Remarkably, further 
analysis of these data 31 identified stathmin-2 to be among the 25 most abundant actively 
translated mRNAs isolated from adult motor neurons in mice. Similarly, our analysis of 
RNA sequencing from laser capture microdissected (LCM) human lumbar spinal motor 
neurons from seven healthy controls 31 determined that in human spinal motor neurons 
stathmin-2 is the 20th most abundant mRNA, only slightly less abundant that the mRNAs 
encoding the three neurofilament subunits NF-M, NF-L and NF-H (Supplementary Fig. 5b). 
Further, of the four stathmin genes, only stathmin-2 was enriched within human motor 
neurons (Supplementary Fig. 5c).
Suppression of stathmin-2 by premature polyadenylation is a hallmark of ALS
Analysis of the RNA sequencing reads mapping to the stathmin-2 gene from lumbar motor 
neurons captured by laser microdissection revealed a clear segregation between controls and 
sporadic ALS cases. RNAs from all analyzed sporadic ALS patients (n=13) contained 
inclusion of exon 2a (Fig. 4a and Supplementary Fig. 6). In contrast, RNAs including exon 
2a were absent in mRNA from all tested (n=7) non-ALS individuals. Importantly, just as we 
had determined in TDP-43 mutant expressing SH-SY5Y cells and patient-derived iNeurons 
(Fig. 1 and 2), overall stathmin-2 mRNA levels in sporadic ALS patients were significantly 
decreased relative to those in motor neurons from non-ALS individuals (Fig. 4b). By 
contrast, stathmin-1 mRNA expression was low in both healthy and ALS spinal motor 
neurons (Fig. 4b). Additionally, analysis of RNAs extracted from anterior horns of thoracic 
spinal cord from 13 sporadic ALS patients and three familial ALS patients carrying 
GGGGCC expansion in C9orf72 revealed aberrant processing of stathmin-2 mRNA in all, 
but not in RNAs from eight healthy individuals or three familial ALS patients with SOD1 
mutations (Fig. 4c and Supplementary Fig. 7a). Consistent with the latter, mice developing 
fatal motor neuron disease from expressing an ALS-linked mutation in SOD1 retained 
normal stathmin-2 mRNA levels despite apparent motor neuron damage 30, demonstrating 
that stathmin-2 expression is not affected by motor neuron degeneration per se 
(Supplementary Fig. 5a). Recognizing that TDP-43 pathology is found in sporadic and 
familial ALS linked to C9orf72 expansion 32 but not SOD1-mediated ALS (Supplementary 
Fig. 8) 33, these results are consistent with premature polyadenylation of stathmin-2 mRNA 
being triggered by TDP-43 dysfunction and the corresponding suppression of stathmin-2 
expression in both thoracic (Fig. 4c and Supplementary Fig. 7a) and lumbar (Fig. 4a) motor 
neurons.
Extension of similar analyses to the motor cortex identified altered processing of stathmin-2 
mRNA to include exon 2a in 2/2 C9orf72 samples and 6/9 sporadic ALS samples (Fig. 4d). 
For ALS cases that were also diagnosed with frontotemporal dementia (FTD), premature 
polyadenylation was seen in frontal cortex-derived RNAs in 3 of 4 sporadic ALS/FTD 
patients, and one of one C9orf72 expansion patient (Supplementary Fig. 7b).
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Lastly, chromogenic in situ hybridization (CISH) was used to test on a cell by cell basis for 
stable accumulation of exon 2a-containing stathmin-2 RNAs in spinal cord and motor cortex 
samples from five control individuals and four sporadic ALS patients (Fig. 4e-g and 
Supplementary Fig. 7c,d). In agreement with prior analyses of RNAs derived by laser 
microdissection (Fig. 4a) or from bulk tissues (Fig. 4c,d), RNA probes hybridizing to 
stathmin-2 exon 2a were increased in both nuclear and cytoplasmic compartments of spinal 
cord neurons (97% of sporadic ALS motor neurons versus 0% of control; n=69 and 41, 
respectively) and in neurons from layers 3 and 5 of motor cortex from all ALS-derived 
samples, with 100% of scored sporadic ALS cortical neurons staining positive for exon 2a 
(n=50) versus 0% of control cortical neurons (n=50). Low basal levels of hybridization 
(presumably corresponding to the newly transcribed stathmin-2 pre-mRNA) were found in 
tissues from non-ALS individuals, with an intensity only slightly above that of a scrambled 
sequence control probe.
A probe hybridizing to exon five of the stathmin-2 mRNA revealed an apparent reduction in 
affected regions of sporadic ALS, with only 35% of sALS lumbar motor neurons showing 
weakly positive staining for STMN2 exon five versus 70% of control patient motor neurons 
(n=65 and 61, respectively). The reduction of exon five staining was even more substantial 
in the motor cortex where 0% of scored neurons showed a positive signal, compared with a 
strong signal in 100% of non-ALS cortical neurons (Fig. 4e,f and Supplementary Fig. 7c,d).
Impaired axonal regeneration upon TDP-43 loss in human iPSC-derived motor neurons is 
alleviated by restoring stathmin-2
To determine the functional consequence of TDP-43-mediated reduction in stathmin-2, 
induced pluripotent stem cells (iPSC) were generated using a non-integrating approach, 
validated to retain a normal karyotype (Supplementary Fig. 9a) and expression of pluripotent 
stem cell markers (Supplementary Fig. 9b-d), and differentiated into motor neurons 
(Supplementary Fig. 9e). Motor neuron precursors (expressing Hb9) appeared within 21 
days (Supplementary Fig. 9f) and by 28 days developed Map2 positive dendrites and long 
axons accumulating neurofilaments (Supplementary Fig. 9g-h). At day 29, motor neurons 
were treated with antisense oligonucleotides (ASOs) that direct catalytic degradation of 
TDP-43 mRNAs through the action of endogenous RNase H. TDP-43 mRNA levels were 
reduced in a dose-dependent manner (Fig. 5a).
ASO-induced reduction in TDP-43 mRNA (up to 55%) was consistently accompanied by a 
greater (up to 12 fold) dose-dependent reduction in stathmin-2 mRNAs, coupled with a 
corresponding increase in RNAs containing exon 1 ligated to exon 2a (Fig. 5b). Dose-
dependent suppression (up to 15 fold) of stathmin-2 expression in iPSC-derived motor 
neurons (without affecting TDP-43 levels) was also achieved with an ASO targeted to the 3’ 
UTR of full length stathmin-2 mRNA (Fig. 5c). Immunoblotting confirmed that within 12 
days of treatment with ASOs targeting either TDP-43 or stathmin-2 mRNAs there was 
nearly complete loss of the 22kD stathmin-2 protein (Fig. 5d). Motor neuronal viability was 
not affected under these conditions (Supplementary Fig. 9i).
To assess the functional consequences of stathmin-2 depletion in the axonal regeneration 
process (Fig. 5e), motor neuron precursors were seeded into the proximal somatic 
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compartment of a microfluidic device. Over a nine days maturation period, axons extended 
through microgroove-embedded channels (830 μm in length) that exclude neuronal cell 
bodies but allow axonal extension into the distal compartment. Matured motor neurons were 
treated for 20 days with ASOs added to the somatic compartment to reduce synthesis and 
accumulation of either TDP-43 or stathmin-2 (Fig. 5f). Axons were maintained after loss of 
either protein. After axons in the distal compartment were mechanically axotomized, axonal 
regrowth of motor neurons treated with non-targeting, control ASOs initiated within 24 
hours (visualized by NF-H immunostaining in red - Fig. 5g-h). Stathmin-2 appeared in a 
punctate pattern along these regenerating axons and accumulated in the growth cones (Fig. 
5g), consistent with a role in promoting axonal regrowth. Indeed, following ASO-mediated 
reduction in stathmin-2 (Fig. 5i,j) or TDP-43 (Fig. 5k,l), axonal regeneration after axotomy 
was almost completely suppressed, with 10% (Fig. 5j) and 13% (Fig. 5l) recovery rates 
relative to those treated with control ASOs, respectively. Together, these data demonstrate 
increased vulnerability of motor neurons upon reduced accumulation of the neuronal-growth 
factor stathmin-2.
We next tested if the failure to regenerate after axotomy of iPSC-derived human motor 
neurons following depletion of either stathmin-2 or TDP-43 could be rescued by restoration 
of stathmin-2 expression. To do this, after a 16 day ASO-mediated suppression of stathmin-2 
or TDP-43, iPSC-derived motor neurons were transduced with a lentivirus carrying a 
stathmin-2-encoding gene whose RNA did not contain the cryptic polyadenylation site found 
in the endogenously encoded stathmin-2 gene. Despite a sustained reduction in stathmin-2, 
subsequent restoration of stathmin-2 expression almost completely rescued regeneration 
after axotomy (Fig. 5m,n). More remarkably, although TDP-43 affects the levels or splicing 
of many RNAs (Fig. 1b and ref. 8,9), restoration of stathmin-2 alone was sufficient to rescue 
regeneration after axotomy of TDP-43 depleted motor neurons (Fig. 5o,p).
Discussion
Using three independent approaches, we have identified that reduction or mutation in 
TDP-43 induces aberrant processing of stathmin-2 pre-mRNA, leading to efficient usage of 
a cryptic polyadenylation site that truncates mRNAs encoding stathmin-2, thereby 
suppressing stathmin-2 synthesis. Our data strongly support that under normal conditions 
TDP-43 acts to maintain stathmin-2 expression by repressing this premature polyadenylation 
within intron one of the stathmin-2 pre-mRNA. Loss of nuclear TDP-43 is a nearly universal 
pathological hallmark in ALS, and notably, we observed efficient premature polyadenylation 
of stathmin-2 in motor neurons of all tested sporadic ALS patients and in patients with 
repeat expansion in C9orf72, the most common inherited cause of ALS and FTD. In 
contrast, altered processing of stathmin-2 was not found in SOD1 ALS patients who do not 
exhibit TDP-43 pathology. Thus, our data offer strong support that loss of stathmin-2 RNA 
by premature polyadenylation and subsequent reduced levels of stathmin-2 protein in 
affected neurons are hallmarks of sporadic and C9orf72-expansion mediated ALS and FTD.
Thousands of mRNA targets affected by TDP-43 dysfunction have been identified in 
multiple cell lines and in vivo 8,9,11,25. Notably, reduced TDP-43 has been linked to the 
abnormal inclusion of a set of cryptic exons that may lead to nonsense-mediated decay and 
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reduced levels of transcripts in different cell types and tissues from mouse and human 
10,34–36
. To that, we have established here that TDP-43 also acts in the normal situation to 
suppress polyadenylation within exon 2a in stathmin-2 pre-mRNA. Reduced TDP-43 in 
human motor neurons is accompanied by nearly complete loss of expression of functional 
stathmin-2. Recognizing that splicing typically occurs co-transcriptionally 37, it is likely that 
the premature polyadenylation in stathmin-2 mRNA is the driving event in stathmin-2 
suppression, with premature polyadenylation inducing the splicing machinery to use a 
previously cryptic 3’ site to resolve splicing initiated at the normal 5’ splice site in intron 
one.
We note that abnormal processing of stathmin-2 is not recapitulated in mice expressing 
TDP-43 transgenes or in TDP-43 deficient mice, as the cryptic polyadenylation signal and 
three GU-rich sequences in intron one of the human stathmin-2 gene are not found in the 
corresponding mouse intron (Supplementary Fig 4d). Consistently, stathmin-2 pre-mRNA is 
not bound by TDP-43 in the murine nervous system and stathmin-2 mRNA level is not 
altered upon ASO-mediated reduction of TDP-43 in wild-type mice 8. By mining TDP-43 
iCLIP data 9, we have identified physical interaction of TDP-43 with exon 2a of human 
stathmin-2 pre-mRNA. This strongly supports that in healthy neurons TDP-43 binding 
represses premature polyadenylation of stathmin-2 pre-mRNA. TDP-43 loss of function 
during disease relieves this inhibition, producing exon 2a-containing, truncated stathmin-2 
mRNAs as seen in all sporadic and C9ORF72-mediated ALS examples tested here.
Our evidence supports a broader role for TDP-43 in modulating polyadenylation within the 
nervous system, similar to the role previously shown for the neuronal factor Nova 38, as well 
as additional RNA-binding proteins 39,40 including the ALS-associated protein FUS 12,41. 
Since computational analysis has recently identified extensive alternative polyadenylation in 
cerebellum of C9orf72 ALS and sporadic ALS subjects 42, as well as in HEK293 cells with 
TDP-43 suppression 43, the global impact of TDP-43 on alternative polyadenylation in 
human motor neurons should now be determined.
Impaired microtubule dynamics has been widely implicated in neurodegeneration, and 
microtubule-stabilizing agents have been proposed as a therapeutic approach 44. While 
disruption of TDP-43 nuclear function affects the processing of numerous RNA targets, our 
data provide a link between increased motor neuron vulnerability in ALS and suppression of 
stathmin-2, a tubulin binding protein previously established to affect microtubule dynamics 
18
. The family of vertebrate stathmins includes stathmins 1–4 that are likely to serve both 
complementary and distinct functions in the nervous system 20. Each stathmin possesses two 
conserved tubulin-binding domains that are capable of interacting with two α/β tubulin 
heterodimers 20.
Individual stathmins may have unique functional properties. Stathmins-2 and 4 are highly 
expressed in neurons 16, with only stathmin-2 mRNA enriched in motor neurons 
(Supplementary Fig. 5b, c). Increased expression of stathmin-1 and stathmin-2 has been 
reported in cellular and mouse models of spinal muscular atrophy (SMA) 45 and in motor 
neurons of SMA-like mice 45 and ALS mice expressing mutant superoxide dismutase 1 
(SOD1) 46,47. Stathmin-2 has been proposed as a neuronal regeneration marker 22 (with 
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expression similar to the axonal growth associated protein GAP-43 48) and we have shown 
here that axonal regeneration after reduction in TDP-43 can be restored by maintaining 
stathmin-2 levels (Fig. 5). In contrast, reduction in stathmin-1, which we show to be 
expressed in motor neurons at 1/30th the level of stathmin-2 (Fig. 4b), has been reported to 
rescue axonal pathology in motor neurons in pmn mice that have mutation in the TBCE 
chaperone for folding tubulin 49.
The stathmin-2 loss we have identified in motor neurons from ALS patients is strongly 
expected to alter microtubule dynamics and function, thereby contributing to denervation 
from neuromuscular junctions and/or axonal degeneration. This scenario is supported by 
evidence of destabilized neuromuscular junctions and impaired synapse stability in 
Drosophila expressing mutant stathmin 23. Likewise, a paralytic phenotype was shown in 
Drosophila following stathmin silencing 50. The high level of stathmin-2 shown here to 
accumulate in normal human spinal motor neurons highlights the potentially deleterious 
impact from its profound reduction upon reduced nuclear TDP-43 function in the neuronal 
population preferentially affected in ALS.
To this, our data provide evidence that reduction in stathmin-2, as the consequence of 
neuronal damage or stress that leads to diminished nuclear TDP-43 function, is itself 
sufficient to inhibit regeneration of motor axons. Restoring the regenerative capability to 
iPSC-derived motor neurons depleted of TDP-43 simply by restoring stathmin-2 levels 
offers a new insight into how TDP-43 dysfunction drives increased vulnerability. Perhaps 
most importantly, our evidence supports development of therapeutic strategies for ALS, FTD 
and other neurodegenerative diseases affected by TDP-43 proteinopathy through restoration 
of stathmin-2 to increase sustainability of affected neurons.
Experimental Procedures
RNA extraction and cDNA synthesis
For RNA extraction from cultured cells and neurons, direct lysis was applied using Trizol 
reagent (Invitrogen) and RNA was purified according to the manufacturer’s instructions. 
Human tissue samples were first homogenized in Trizol, using a mechanical tissue 
homogenizer, and RNA was extracted accordingly.
RT-PCR and real-time PCR
For cDNA synthesis, 1 μg total RNA was reverse transcribed using the high-capacity reverse 
transcription kit (ABI) or superscript III (Invitrogen) according to the manufactures’ 
instructions. RT-PCR reactions were performed using Q5 High-Fidelity DNA polymerase 
(NEB) in a T100 thermocycler PCR machine (Bio-Rad). For splicing analyses, RT-PCR 
products were separated on 2% polyacrylamide gels and then incubated with SYBR gold 
(Invitrogen) for imaging and analysis. Quantification of alternative splicing band intensities 
were determined using ImageJ software and an average of 3 biological replicates was 
plotted. Quantitative real-time PCR was carried out in triplicates, using iTaq Universal 
SYBR green (Bio-Rad) in a CFX384 real-time PCR machine. mRNA expression of 
transferrin receptor protein-1 (TFRC) and glyceraldehyde-3-phosphate dehydrogenase 
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(GAPDH) were used as endogenous control genes, as indicated. All primers are listed in 
Supplementary Table 4.
RNA sequencing
Total RNA was extracted from SH-SY5Y cells as indicated above. Subsequently, 1 μg of 
total RNA was used for mRNA libraries preparation using the TruSeq RNA kit (Illumina). 
For the TDP-43 knockdown experiment, 3 biological replicates were sequenced per each 
condition (siControl/siTDP-43). For TDP-43 genome-editing experiments, 2 biological 
replicates were sequenced per each condition (TDP-43WT/WT, TDP-43N352S/N352S). Real-
time qPCR validations were done with at least 3 replicates. RNA sequencing was carried out 
on an Illumina HiSeq 4000 platform with a median of 46M reads per sample. 50bp single-
end FASTQ files were obtained using the Illumina demultiplexing pipeline. STAR 54 and 
RSEM 55 were used to align the reads to the human reference sequence HG38 and to 
calculate the raw counts and transcripts per million (TPM) values for genes, respectively. 
Genes differentially expressed between sample groups were identified by DESeq2 51.
Genome editing
Both TDP-43 alleles were genetically modified in SH-SY5Y cells. A single guided RNA 
targeting TDP-43 was designed (Benchlin webtool) and cloned into pSpCas9–2A-GFP 
plasmid 56 (px458-Addgene) using the BbSI restriction site. The sequence for guided RNA 
targeting TDP-43 is: GCGGGTAATAACCAAAACCA. To promote homologous 
recombination, pSpCas9–2A-GFP-gRNA plasmid was electroporated using the Amaxa 
Nucleofactor (assay A-023) along with a 180 long single-stranded donor oligonucleotides 
(IDT), containing the desired ALS-causing mutation and four synonymous single-nucleotide 
replacements to avoid DNA cleavage recurrence by Cas9. 48 hours following 
electroporation, cells were collected and dissociated using Accutase. GFP-positive cells 
were sorted and single-cell seeded into 96 wells plates using the SH800S Sony cell sorter. 
Individual clones were expanded and DNA was extracted for PCR amplification of TDP-43 
genomic locus. Replacement of AAT to AGT (c.1055A>G) was confirmed by Sanger 
sequencing. The entire TDP-43 coding region and all exon-intron junctions (> 500 base-
pairs length of each intronic region) were then sequenced to verify the absence of any 
additional DNA alteration. qPCR analysis was performed with a wild type isogenic SH-
SY5Y cell line that had undergone the mutagenesis attempt but not acquired the TDP-43 
mutation during the original screening progress.
Immunoblotting
Total-cells extracts were collected in radioimmunoprecipitation lysis buffer (RIPA buffer). 
Proteins concentrations were determined by Bradford assay (Bio-Rad) and equal amounts of 
total protein were boiled in SDS sample buffer for 10 minutes before running in 10% 
acrylamide gel. Proteins were transferred to PVDF, and blocked in 5% milk solution in tris-
buffered saline and 0.1% Tween-20 (TBST) for 1 hour before overnight incubation with the 
following primary antibodies: anti-TDP-43 (1:1000) (ProteinTech, 10782–2-AP), anti-
Stathmin-2 (1:2000) (nbp1–49461, NovusBiologicals), anti-Tubulin (1:10,000) (DM1A, 
Abcam). Immunoblots were washed in TBST and probed with HRP-conjugated secondary 
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antibodies diluted 1:5000 for one hour in room temperature (GE Healthcare), before being 
exposed to films.
Immunofluorescence and image acquisition
SH-SY5Y cells were grown on poly-D-lysine (Sigma) coated 4-wells glass bottom chambers 
(Thermo). iNeurons were grown on matrigel coated (Corning, 356230) 4-wells glass bottom 
chambers (Thermo). At end point, cells were washed one time with phosphate buffer (PBS) 
and fixed by 4% paraformaldehyde in phosphate buffer (PBS) for 30 minutes at room 
temperature. Two washes with PBS were followed by cell membrane permeabilization using 
0.1% Triton X-100 (Sigma) for 15 minutes at room temperature. After one wash with PBS, 
cells were incubated for 30 minutes with blocking solution containing 3% bovine serum 
albumin (Sigma) + 3% donkey serum (Jackson ImmunoResearch) in PBS. Blocking solution 
was removed and replaced with primary TDP-43 antibody (Proteintech # 10782–2-AP) 
diluted 1:1000 in fresh blocking solution for overnight incubation at 4°C. Following 
overnight incubation and 3 washes with PBS, cells were incubated with fluorescently tagged 
secondary antibody conjugated to Alexa-488 (Thermo Fisher Scientific) diluted 1:500 in 
blocking solution. Finally, cells were washed 3 times in PBS, the second wash included 10 
minutes incubation with DAPI solution (Thermo Fisher Scientific, 100ng/ml) for nuclear 
staining. The preparation was mounted with ProLong Gold antifade reagent (Thermo Fisher 
Scientific). Fluorescence images were acquired with Olympus FV1000 confocal microscope, 
at the microscopy core, the Ludwig institute, UCSD.
Fluorescence quantification from micrographs
Fluorescence quantifications were performed using FIJI image processing software (http://
imagej.net). Freehand tool of the software was used to select the subcellular regions such as 
nuclei or cytoplasm for quantification. Data were plotted in GraphPad Prism software for 
illustration.
In Situ Hybridization of STMN2 RNA isoforms
Short 5’-Digoxigenin-labeled Locked Nucleic Acid (LNA) probes were designed by 
QIAGEN (Truncated Exon2A STMN2 RNA isoform probe sequence: 
TCACACAGAGAGCCAAATTCTT; Normal STMN2 mature mRNA probe sequence to the 
3’UTR of STMN2: ATCCTGATATCGCATGATCCAT). For each tissue two serial FFPE 
tissue sections (7μm) were cut onto charged glass slides. Each of the two sections was 
hybridized with one of the STMN2 probes using standard ISH protocols and revealed with a 
commercial anti-DIG antibody and NBT developer kit. Slides were inspected under 
brightfield microscopy and serial sections of individual neurons were identified and imaged 
at 40x magnification on a Keyence BZ-X700 fluorescent microscope. For quantification, 
spinal motor neurons were identified by their large cytoplasm and/or nucleus, the presence 
of lipofuscin, and their position within Rexed lamina IX of the spinal cord. Neurons of the 
motor cortex were identified by their shape and relative size and position within cortical 
layering, with special attention to layers 3 and 5.
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Immunohistochemistry for TDP-43 and phosphorylated TDP-43
Formalin-fixed paraffin-embedded sections with 6 µm thickness were deparaffinized with 
Citrisolv (Decon Lab #1601H) and hydrated with different dilutions of alcohol. Endogenous 
peroxidase activity was quenched with 0.06% H2O2 in methanol for 15 min. Antigen 
retrieval was performed in a high pH solution (Vector #H-3301) in a pressure cooker at 
125 °C for 20 min. Sections were blocked with 2% FBS (Gibco #10438–026) and 0.2% 
Triton X-100 (Sigma #T8787) in PBS for 60 min. Following antigen retrieval and blocking, 
the sections were incubated with primary antibodies at 4 °C overnight as follows: TDP-43 
(anti-Rabbit, Proteintech #10782–2-AP, 1:5,000) and phosphorylated TDP-43 (pTDP-43) 
(pS409/410, anti-Rabbit, Cosmobio #TIP-PTD-P02, 1:1,000). The secondary antibody 
(ImmPRESS HRP Reagent Kit, anti-Rabbit IgG, Vector #MP-7401) was incubated at room 
temperature for 60 min, and signals were detected using NovaRED peroxidase substrate kit 
(Vector #SK-4800) for 2 minutes. Counterstaining was performed with hematoxylin (Ricca 
chemical #3537–32). TDP-43 and pTDP-43 immunohistochemistry was performed using 
consecutive sections for each patient.
Cell culture and transfection
SH-SY5Y—The neuroblastoma cells (ATCC) were cultured in DMEM/F12 (Gibco) 
supplemented with 10% fetal-bovine serum (Omega) and 1% penicillin-streptomycin 
(Gibco) at 37 °C with 5% CO2. For knockdown experiments, cells were transfected with 
SMARTpool ON-TARGETplus siRNA targeting TDP-43 (L-012394) or control siRNA pool 
(D001810–10) (GE Dharmacon) at final concentration of 50nM, for 96 hours in two doses 
(0, 24h), after complexing with Lipofectamin RNAiMAX (Invitrogen) in Opti-MEM 
(Gibco) for 20 minutes.
Fibroblasts—Fibroblasts were cultured in DMEM/F12 (Gibco) containing 20% 
tetracycline-free FBS (Omega) and 1% penicillin-streptomycin (Gibco).
Direct conversion of human fibroblasts into induced neurons—The trans-
differentiation assay was performed according to a protocol previously described 57 and is 
based on expression of neuronal-specific transcriptional factor Brn2 and knockdown of the 
splicing factor PTB. Briefly, initial lentiviral transduction of fibroblasts by doxycycline-
induced Brn2 expressing plasmid was performed. After 16 hours, mediia was replaced and 
cells were allowed to recover for 24 hours. Cells were then grown under 1 μg/ml puromycin 
selection (Gibco) for 4 days and remaining cells were transferred into a new culturing dish. 
After expansion to 40–50% confluency, cells were transduced with shRNA lentivirus 
designed to suppress PTB mRNA expression. 16 hours later, medium was replaced for 24 
hours recovery. After selection with hygromycin B (100µg/ml) for 4 days, remaining cells 
were seeded for terminal differentiation in matrigel-covered (Corning, 356230) glass 
chambers (Thermo) for Immunofluorescence or 6 well dish for RNA extraction. 24 hours 
later, medium was switched to 1:1 DMEMF12:Neurobasal N3 medium plus doxocycline 1 
μg/ml (Dox) (Sigma), FGFb 10ng/ml (Invitrogen) and 0.4% B27 (Gibco). The N3 medium 
contains: 25 μg/ml insulin (Sigma, I9278), 50 μg/ml apo-transferrin (T1147), 30 nM sodium 
selenite, 20 nM progesterone (Sigma), 100 nM putrescine (Sigma), 0.4% B27 and penicillin/
streptomycin (Gibco). Small molecules were added 48 hours later: CHIR99021 1μM 
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(Stemgent, 04–0004-02), SB431542 10μM (Stemgent, 04–0010) and Dbcamp 0.5 μM 
(Sigma, D0627). 48 hours later, cells were switched to N3 medium containing neuronal 
growth factors: CNTF (20ng/ml), BDNF (10ng/ml), NT3 (10ng/ml) and GDNF (20ng/ml) 
purchased from R&D systems, plus 2% FBS, Dox (1μg/ml), FGFb (10ng/ml), 0.4% B27, 
forskolin 10μM (FSK) (Sigma F6886) and DM 1μM (AMPK Inhibitor, Compound C; 
Millipore 17126). Medium was changed every other day for 2–4 weeks.
Induced pluripotent cells (iPSC) and motor neurons differentiation—The iPSC 
line was derived from peripheral blood mononuclear cells donated by a 58 year old healthy 
Caucasian male, by introducing the episomal DNAs expressing Oct4, Sox2, Klf4, L-Myc, 
Nanog, and shRNA against p53. The selected clone was fully characterized and 
demonstrated a normal karyotype with normal self-renewal and differentiation capacity 
comparable with H9 human embryonic stem cells. NextGen sequencing data shows that no 
modifications occurred on ALS-related genes. iPS cells were differentiated into motor 
neurons using the proprietary differentiation protocol patented by iXCells Biotechnologies 
(Provisional Application # 14359–001-888), summarized in Supplementary Fig. 9.
Antisense oligonucleotide (ASO) treatment—ASOs mediating RNase H-dependent 
degradation of the TDP-43 mRNA, AAGGCTTCATATTGTACTTT, Ionis Pharmaceuticals), 
stathmin-2 mRNA, GGTCTTAGTCAAGCTCAGAG, Ionis Pharmaceuticals), or murine 
Malat-1 as control, GGGTCAGCTGCCAATGCTAG, Ionis Pharmaceuticals), were added to 
the iPSC-derived motor neurons culture medium at day 29 of maturation. Medium was 
changed every 3–4 days without addition of ASOs, and RNA was collected after 12 days of 
treatment (day 41). The MOE-gapmer ASOs are 20 nucleotides in length, wherein the 
central gap segment comprising ten 2′-deoxyribonucleotides that are flanked on the 5′ and 
3′ wings by five 2′-O-methoxyethyl-modified nucleotides. The internucleotide linkages are 
phosphorothioate, except for the Stathmin-2 ASO which has phosphodiester linkages in the 
5’ and 3’ wings of the ASO, and all cytosine residues are 5′-methylcytosines.
Compartmentalized microfluidic devices and axotomy—The master molds to 
prepare the microfluidic devices were fabricated by photolithography, as previously 
described (Minteer, 2006), by the Bioengineering Department of the University of 
California, San Diego, Nano3 Cleanroom Facility. Two compartment devices were molded 
by soft lithography using Sylgard 182 (Ellsworth Adhesives, Germantown, WI) as 
previously described 58. Each compartment of the device was 108 μm tall, separated by 
microgrooves 3.1 μm tall, 16.28 μm wide and 830 μm long. The proximal compartment 
contained one hole in each side of the compartment 8 mm in diameter, while the distal 
compartment’s holes were 4 mm in diameter. These characteristics are important to perform 
an effective vacuum-based axotomy. After curing, the cut devices were bath-sonicated in 
water, washed in 70% ethanol and sterilized under UV before mounting onto glass 
coverslips. The devices were coated with matrigel (Corning, 356230) for 1 hour at 37ºC and 
rinsed with DMEM before plating the cells. Half million iPSC-derived motor neuron 
precursors were plated in the proximal somatic compartment, and axonal growth to distal 
compartment was achieved in eight days of maturation. ASOs were then added into the 
somatic compartment for 20 days of treatment, half media was changed every 4 days and a 
Melamed et al. Page 14
Nat Neurosci. Author manuscript; available in PMC 2019 July 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
second dose of ASOs was added at day 12. For aspiration-induced axotomy, media was 
simultaneously aspirated from one side and added back to the other side of the distal 
(axonal) compartment, until complete removal of axons from the distal compartment was 
confirmed.
Lenti-viral transduction—A stathmin-2 open reading frame was cloned into a PL-
SIN18-lentiviral vector under transcriptional control of the phosphoglycerate kinase (PGK) 
promoter. HEK293T cells were used for packaging lentiviruses. Briefly, 0.5 ×106 per well of 
293T cells were seeded in a 6-well plate. For lentiviral transfection, 2.5 µg of the lentiviral 
plasmid (containing stathmin-2 cDNA), 1.25 µg of pMD2.G and 0.625 µg of psPAX2 were 
co-transfected to each well using Mirus transIT-X2 transfection reagent (Mirus). Culture 
medium was changed to fresh medium at ~24 hours post transfection. Virus containing 
supernatants were collected at 48h and 72h after transfection and concentrated using 
ultracentrifugation. Viral concentrates were stored at −80 °C. Human iPSC-derived motor 
neurons were cultured to maturation and then infected with lentiviral particles encoding 
stathmin-2 in the presence of polybrene (Millipore).
Cell viability assay—Human iPSC-derived motor neurons were matured as described in 
supplementary Fig. 9e, and then treated with control ASOs or ASOs targeting TDP-43 or 
stathmin-2 for 20 days. Viability of iPSC-derived human motor neurons was examined using 
LIVE/DEAD Reduced Biohazard Viability/Cytotoxicity Kit (Molecular Probes), according 
to the manufacturer’s instructions. Quantification of living cells was performed using the 
Olympus FV1000 confocal microscope.
Human postmortem tissues—Human tissues were obtained using a short postmortem 
interval acquisition protocol that followed HIPAA-compliant informed consent procedures 
and were approved by Institutional Review Board (Benaroya Research Institute, Seattle, WA 
IRB# 10058 and University of California San Diego, San Diego, CA IRB# 120056).
Tissue samples were obtained from patients who met the modified El Escorial criteria for 
definite ALS (Brooks et al, 2000). Control nervous systems were obtained from non-
neurological patients when life support was withdrawn, or from patients on hospice. 
Autopsies were performed within 10 hours of death, with an average post-mortem interval of 
5 hours for the cohort of patients used in this study.
Information on human samples is provided in Supplementary Table 5.
Statistics—Statistical tests were performed using GraphPad Prism. Student’s t-test (two 
tails or one tail) were used as indicated in the text. No statistical methods were used to pre-
determine sample sizes but our sample sizes are similar to those reported in previous 
publications. Experiments were not randomized. Data distribution was assumed to be normal 
but this was not formally tested. Data collection and analysis were not performed blind to 
the conditions of the experiments.
Reporting summary—Extended information on experimental design is available in the 
Life Sciences Reporting Summary linked to this article.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. TDP-43 depletion or genome editing in a human neuronal cell line identifies significant 
reduction in stathmin-2 expression levels.
(a) Quantitative real-time PCR analysis confirming siRNA-mediated reduction of TDP-43 
mRNA levels in SH-SY5Y cells. Expression of TRFC and GAPDH mRNAs were used as 
endogenous controls. Cells were treated with siControl (white bar, black dots, mean=1) or 
siTDP-43 (gray bar, red dots, mean=0.19) for 96 hours in three biologically independent 
experiments (two-tailed t-test, P=0.0012, n=3), error bars represent SEM, **P<0.01. (b) 
Volcano-plot showing differentially expressed genes in SH-SY5Y cells depleted of TDP-43 
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by siRNA treatment. Genes with significant changes in mRNA levels are represented by red 
dots (n=3 biologically independent experiments, fold change >1.5 and FDR<0.05) by 
DESeq2 51. Increased red dot size represents increased statistical significance (measured by 
FDR<0.05). RNA-seq analysis identified 518 misregulated genes and confirmed 4 fold 
reduction in TDP-43 mRNA levels. Stathmin-2 mRNA showed the strongest reduction (6.5 
fold) upon TDP-43 depletion. Up and down regulated genes’ counts are indicated. 
Expression values were determined as transcripts per kilobase per million mapped reads 
(TPM). (c) Quantitative real-time PCR analysis confirming reduction of stathmin-2 mRNA 
expression levels (mean=0.13) in SH-SY5Y cells treated with siRNA targeting TDP-43 
compared to cells treated with siControl (mean = 1) for 96 hours in three biologically 
independent experiments (two-tailed t-test, P=0.0005, n=3), error bars represent SEM. 
***P<0.001 (d) Immunoblotting of TDP-43 and stathmin-2 in SH-SY5Y cells treated with 
siControl or siTDP43 for 96 hours. α-tubulin served as a loading control. Three biological 
replicates are shown. (e) Representative Immunofluorescence of TDP-43 (green) and lamin-
B (red) in SH-SY5Y lines expressing wild type or mutant TDP-43 by genome-editing. 
Genotypes are indicated, experiment was reproduced 3 times independently with similar 
results. For unprocessed blots, see Supplementary Fig. 10. (f) Volcano plot depicting 950 
differentially expressed genes identified by genome-wide RNA-seq. Significant changes in 
mRNA levels between SH-SY5YWT and SH-SY5YN352S/N352S lines are represented by red 
dots (n=2 biologically independent experiments, fold change > 1.5, FDR<0.05) by DESeq2 
51
. Increased red dot size represents increased statistical significance (measured by 
FDR<0.05). Expression values were calculated as transcripts per kilobase per million 
mapped reads (TPM). (g) Quantitative real-time PCR analysis confirming significant 
reduction in stathmin-2 mRNA levels between isogenic SH-SY5YWT/WT (white bar, black 
dots, mean=1) and SH-SY5YN352S/N352S (black bar, red dots, mean=0.58) lines. Expression 
of TRFC and GAPDH mRNAs were used as endogenous controls (two-tailed t-test, 
P=0.004, n=3 independent biological experiments), error bars represent SEM. **P<0.01. (h) 
Expression changes of 42 overlapping genes from figures 1b and 1f are plotted.
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Figure 2. Reduced stathmin-2 levels in human neurons produced by direct conversion from ALS 
patient fibroblasts expressing mutant TDP-43.
(a) Summary of the direct conversion strategy adopted from Xue et al. 2013 28. (b) Induced 
neurons (iNeurons) converted from fibroblasts of control and ALS patient. 
Immunofluorescence staining at day 20 of differentiation revealed partial cytoplasmic 
mislocalization of TDP-43 (green) in ALS iNeurons. Neuron-specific Class III β-tubulin 
(Tuj1) (red) was used as a neuronal marker, cell nuclei are visualized by DAPI staining 
(blue). Experiment was repeated independently with similar results from 3 control 
individuals and 3 familial ALS donor lines (with mutant TDP-43). (c) qPCR analysis of 
stathmin-2 mRNA levels in iNeurons from control (grey bars, black dots) and familial ALS 
patients with different TDP-43 mutations (white bars, turquoise dots). Plotted are 2 
biologically independent experiments per each individual from an extended family that 
included 4 carriers heterozygous for the ALS-linked mutant TDP-43N352S (n=4, mean=0.3) 
and 4 individuals without the mutation (n=4, mean=1). Two-tailed t-test, P = 0.008. Also 
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plotted are three biologically independent experiments of three additional ALS patients 
(non-family members) carriers of the indicated mutations. (d) Summary of stathmin-2 
expression level measured by qPCR in iNeurons from controls (n=4, gray, mean = 1) and 
familial ALS patients (n=7, white, mean=0.36). P=0.0005, two-tailed t-test, SEM. 
**P<0.01***, ***P<0.001.
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Figure 3. TDP-43 regulates stathmin-2 mRNA levels by repressing premature polyadenylation.
(a) RNA-seq reads mapped to the genomic region of stathmin-2 reveal incorporation of a 
new exon, originated from intron 1, into the mature stathmin-2 mRNA. Red arrows indicate 
the intronic region of aberrant splicing (exon 2a) in SH-SY5Y cells upon TDP-43 depletion 
(upper panels) or expression of mutant TDP-43 (lower panels). Experiment was repeated 
independently three times (TDP-43 depletion) or twice (expression of mutant TDP-43) with 
similar results. (b) Representative RT-PCR (left, experiment was repeated 3 times 
independently with similar results) and qPCR (right, n=3 biologically independent 
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experiments) analyses confirmed expression of the new spliced mRNA isoform containing 
exon 2a upon TDP-43 depletion (mean=8.7, P=0.00078) or mutation (mean=3.8, P=0.0001). 
The location of primers in exons 1 and 2a is shown. RT-PCR of the CENP-A transcript was 
used as loading control for RT-PCR, TFRC and GAPDH were used as qPCR normalizers 
(***p<0.001, two-tailed t-test, SEM). For uncropped gel images, see Supplementary Fig. 10. 
(c) Schematic representation of stathmin-2 pre-mRNA (upper panel) and alternative RNA 
isoforms (lower panels) in normal cells (i) or cells with TDP-43 deficiency (ii). Constitutive 
exons are represented by black boxes, exon 2a is in red and the thin red box represents the 
newly acquired 3’UTR. Light grey boxes represent 3’ or 5’ UTRs of normal stathmin-2 
mRNA. (d) Sequence of exon 2a is shown in red, including the embedded in-frame UAG 
codon generating a premature stop codon. Highlighted are potential TDP-43 binding sites 
located 127 upstream of the alternative polyadenylation signal. (e) 3’ end sequencing by 
reverse transcription using oligo(dT)-VN primers confirmed exon 2a as the terminal exon of 
short stathmin-2 mRNA. (f) Genome browser track obtained from cross-linking and 
immuno-precipitation (iCLIP) for TDP-43 in human SH-SY5Y cells 9, revealed TDP-43 
physical binding to exon 2a, located in intron 1 of stathmin-2 pre-mRNA.
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Figure 4. Abnormal stathmin-2 mRNA processing is a disease hallmark in affected spinal motor 
neurons of sporadic ALS patients.
(a) RNA sequencing of control and sporadic ALS laser-captured spinal motor neurons 
reveals robust signature of exon 2a incorporation in stathmin-2 mRNA in sporadic ALS 
samples but not in non-ALS aged controls. Lower diagram shows the genomic region of 
stathmin-2 and mapped RNA reads of exon 2a are indicated by a red arrow. Data analyzed 
from from Krach et al., 2018 31. (b) Stathmin-2 mRNA expression is suppressed in spinal 
motor neurons of sporadic ALS patients (gray bar, n=13, mean = 423 TPM, P=0.03) relative 
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to non-ALS aged controls (white bar, n=7, mean=971 TPM, P=0.019). Two-tailed t-test, 
SEM. RNA sequencing data was analyzed from Krach et al., 2018 31. Stathmin-1 mRNA 
expression is shown to the right (control mean=25, ALS patients mean = 44.5). Transcripts 
per million counts (TPM) are represented, two-tailed t-test. P=0.02. *P<0.05, SEM. (c-d) 
RT-PCR using primers targeted to exon 1 and exon 2a confirms expression of truncated 
stathmin-2 isoform in (c) thoracic spinal cord or (d) motor cortex from sporadic and 
C9orf72 ALS patients, but not in spinal cords of mutant SOD1 carriers. For uncropped gel 
images, see Supplementary Fig. 10 (e-f) Lumbar spinal cord and motor cortex sections 
isolated from control individuals and sporadic ALS patients were hybridized with locked 
nucleic acid (LNA) probes targeting intron one of stathmin-2 pre-mRNA (for the truncated 
RNA) or exon 5 of stathmin-2 pre-mRNA. Signal is in blue, counterstain is nuclear fast red. 
(g) Table summarizing human samples with expression of stathmin-2 truncated RNA, 
identified by RT-PCR or in-situ hybridization. Data from supplementary Fig. 7 is included.
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Figure 5: Impaired axonal regeneration upon TDP-43 loss in human iPSC-derived motor 
neurons is alleviated by stathmin-2 restoration.
(a) Quantitative real-time PCR analysis confirming ASO-mediated reduction of TDP-43 
mRNA (gray, dose-dependent mean values are 0.71, 0.6, 0.43, respectively) or stathmin-2 
mRNA (red, dose-dependent mean values are 0.67, 0.31, 0.09, respectively) levels in human 
iPSC-derived motor neurons. Control bar (white, mean=1) represents 3 biological replicates, 
expression of TRFC mRNA was used as endogenous control. Error bars represent SEM. (b) 
RT-PCR analysis confirmed altered splicing and ligation of exon 1 and exon 2a upon 
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treatment with ASOs targeting TDP-43, in iPSC-derived motor neurons. Three ASO 
concentrations were tested and a dose dependent effect on expression of stathmin-2 short 
RNA is shown. Experiment was reproduced five times independently with similar results. 
For uncropped gel images, see Supplementary Fig. 10. (c) Quantitative real-time PCR 
analysis confirming ASO-mediated reduction of stathmin-2 mRNA (red, dose-dependent 
mean values are 0.23, 0.12, 0.07, respectively) or TDP-43 mRNA (gray, dose-dependent 
mean values are 0.99, 0.95, 1.04, respectively) levels in human iPSC-derived motor neurons. 
Control bar (mean=1) represents 3 biological replicates, expression of TRFC mRNA was 
used as endogenous control. Error bars represent SEM. (d) Immunoblotting of TDP-43 and 
Stathmin-2 in iPSC-derived motor neurons treated with mouse Malat-1 ASO as control (n=2 
biologically independent experiments), TDP-43 ASO (n=2 biologically independent 
experiments) or stathmin-2 ASO (n=2 biologically independent experiments) for 20 days. α-
Tubulin served as a loading control. Stathmin-2 protein was profoundly suppressed 
following TDP-43 ASO or stathmin-2 ASO treatments. Experiment was repeated 
independently five times with similar results. For uncropped blots, see Supplementary Fig. 
10. (e) Schematic illustration of motor neurons in microfluidic chambers before and after 
axotomy. Motor neuron precursors were plated at the somatic/proximal compartment and 
axons reached into the distal/axonal compartment during a maturation period of another 
eight days. One dose of ASOs was added every 12 days to the somatic compartment. After 
20 days of culturing with ASOs, aspiration-based axotomy was performed at the distal 
compartment of each chamber leading to a complete removal of axons in that compartment. 
Recovery was allowed for 24 hours. (f) Timeline of iPSC-derived motor neuron maturation, 
ASO treatment and axotomy is shown. (g,i,k,m,o) Representative confocal 
immunofluorescence images of microgrooves and distal compartments, 24 hours post 
axotomy. Insets show high-magnification of regenerating axons’ growth cones. Axonal 
regeneration and growth cones are observed by immunofluorescence of stathmin-2 (green) 
and NF-H (red) in the terminals of motor neurons treated with control ASOs (g,h) but not in 
motor neurons treated with stathmin-2 (i,j) or TDP-43 (k,l) ASOs. (m,n,o,p) iPSCs-derived 
motor neurons treated with ASOs against stathmin-2 (m,n) or TDP43 (o,p) for 20 days and 
transduced with stathmin-2 expressing lentivirus for the last 96 hours showed axonal 
regeneration with growth cones in all axonal terminals. (h,j,l,n,p) Quantifications of 300 
axons per condition are shown.
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